https://mtimes.net Real-time English, Japanese, and Chinese financial news, South Korean stock market analysis, corporate governance, and global tech supply chain intelligence. en-us Sun, 01 Nov 2026 08:37:12 GMT Copyright 2026 MTIMES Global. All rights reserved. https://mtimes.net/article/1410 https://mtimes.net/article/1410 Sun, 01 Nov 2026 03:17:17 GMT As the KOSDAQ index flirts with the 720 threshold, market participants are increasingly demanding regulatory overhauls, including a ban on short-selling, the abolition of investor-caution designations, and the relaxation of earnings-loss rules tailored to R&D-heavy growth companies. Headline editorial@mtimes.net (Park Hae-soo Reporter) https://mtimes.net/article/1408 https://mtimes.net/article/1408 Sun, 01 Nov 2026 00:44:02 GMT Anthropic is aggressively expanding into the life sciences sector, moving beyond supplying research-grade AI to pharmaceutical firms to directly participating in drug discovery with its own research organization and laboratories. The company plans to deploy its Claude model across target design, experimental data analysis, and clinical trial planning. Corporate editorial@mtimes.net (Song Jung-hee Reporter) https://mtimes.net/article/1406 https://mtimes.net/article/1406 Sat, 31 Oct 2026 06:20:14 GMT After hitting the 1,200-point mark in April, the KOSDAQ index has plunged by more than 40% in six months, widening its performance gap with the KOSPI to 57.7 percentage points. Structural issues, including the migration of blue-chip companies, earnings polarization, and capital flight toward large-cap stocks, continue to weigh on the index 30 years after its inception. Markets editorial@mtimes.net (Choi Jun-hyuk Reporter) https://mtimes.net/article/1409 https://mtimes.net/article/1409 Sun, 01 Nov 2026 00:45:09 GMT POSCO Future M and LG Energy Solution have signed a preliminary agreement to supply 720,000 tons of cathode and anode materials over seven years, marking a strategic shift toward energy storage systems and affordable electric vehicles. Industry editorial@mtimes.net (Park Hae-soo Reporter) https://mtimes.net/article/1405 https://mtimes.net/article/1405 Fri, 30 Oct 2026 22:59:36 GMT Nasdaq plunges 2.86%, chip index slides 7.2%; Intel records worst day in 52 years. Investors shift focus from top-line revenue growth to cash flow sustainability as AI capital expenditure pressures mount. Markets editorial@mtimes.net (Kim Jeong-eun Reporter) https://mtimes.net/article/1407 https://mtimes.net/article/1407 Sun, 01 Nov 2026 00:27:26 GMT Seoul aims to scale up AI adoption among small and medium-sized manufacturing enterprises tenfold by 2030, deploying physical AI and manufacturing robots to bridge a widening technological gap with conglomerates. Industry editorial@mtimes.net (Lee Kyung-hee Reporter) https://mtimes.net/article/1394 https://mtimes.net/article/1394 Fri, 30 Oct 2026 00:15:41 GMT As telecom base stations begin to handle AI computations alongside traditional voice and data traffic, major tech firms like Nvidia, Nokia, and Samsung Electronics are accelerating the development of AI-RAN technologies. This shift could potentially expand the market for GPUs and server memory far beyond traditional data centers. Industry editorial@mtimes.net (Kim Jeong-eun Reporter) https://mtimes.net/article/1379 https://mtimes.net/article/1379 Thu, 29 Oct 2026 00:04:24 GMT Global renewable energy installations hit a record 692 GW last year, driven largely by China, but are projected to decline this year amid a widening grid capacity mismatch. With connection backlogs exceeding 2,500 GW worldwide, experts warn that global grid investments must surge by 50% through 2030 to sustain the green transition. Industry editorial@mtimes.net (Kim Jeong-eun Reporter) https://mtimes.net/article/1377 https://mtimes.net/article/1377 Wed, 28 Oct 2026 22:59:31 GMT Global investment banks and asset managers lean toward a further rate hike in December following the Federal Reserve’s decision to hold rates steady, though divergence remains over next year's monetary policy path. Markets editorial@mtimes.net (Song Jung-hee Reporter) https://mtimes.net/article/1343 https://mtimes.net/article/1343 Mon, 26 Oct 2026 06:39:58 GMT While demand for AI semiconductors remains unabated, the soaring cost of capital has emerged as a significant headwind for massive infrastructure projects, with Elon Musk’s SpaceX facing complex price negotiations for a $40 billion financing deal. Markets editorial@mtimes.net (Song Jung-hee Reporter) https://mtimes.net/article/1338 https://mtimes.net/article/1338 Mon, 26 Oct 2026 00:47:38 GMT Tesla kicks off production and targets external supply by late 2027, while Hyundai Motor plans factory deployment by 2028. As Samsung and LG step up their robotics race, global players face the critical test of proving economic viability beyond mere shipment volumes. Industry editorial@mtimes.net (Kim Jeong-eun Reporter) https://mtimes.net/article/1241 https://mtimes.net/article/1241 Thu, 15 Oct 2026 00:54:49 GMT The U.S. September Consumer Price Index (CPI) report has rattled financial markets, as "sticky" core inflation pressures raise the possibility of an earlier-than-expected interest rate hike by the Federal Reserve. Finance & Securities editorial@mtimes.net (Park Hae-soo Reporter) https://mtimes.net/article/1214 https://mtimes.net/article/1214 Mon, 12 Oct 2026 23:51:43 GMT South Korean biotech firm Mezzion Pharma is expanding its pivotal Phase 3 trial for Udenafil to Europe as it moves toward a potential 2027 FDA filing, with peak annual U.S. sales estimated at $3 billion. Corporate editorial@mtimes.net (Song Jung-hee Reporter) https://mtimes.net/article/1162 https://mtimes.net/article/1162 Tue, 06 Oct 2026 22:55:31 GMT HLB Therapeutics CEO An Ki-hong emphasized that the superior convenience and safety profile of RGN-259 will drive its adoption as a primary treatment for neurotrophic keratitis (NK), with top-line results from the SEER-2 global Phase 3 clinical trial expected by mid-November. Corporate editorial@mtimes.net (Kim Jeong-eun Reporter) https://mtimes.net/article/1146 https://mtimes.net/article/1146 Mon, 05 Oct 2026 21:42:37 GMT HLB Therapeutics is preparing for a make-or-break moment in November, as it awaits the top-line results of its U.S. Phase 3 "SEER-2" trial for the neurotrophic keratitis (NK) treatment candidate RGN-259. The company aims to challenge the U.S. market dominance of Dompé’s "Oxervate," leveraging the logistical advantages of a shelf-stable, short-term treatment regimen. Corporate editorial@mtimes.net (Kim Jeong-eun Reporter) https://mtimes.net/article/1141 https://mtimes.net/article/1141 Sat, 03 Oct 2026 02:18:40 GMT AriBio’s U.S. division head, Fred Kim, outlined the company’s ambition to position its oral Alzheimer’s candidate, AR1001, as a first-line treatment, with global Phase 3 trial results set for release in November 2026. Corporate editorial@mtimes.net (Song Jung-hee Reporter) https://mtimes.net/article/1135 https://mtimes.net/article/1135 Fri, 02 Oct 2026 08:03:16 GMT ArisBio is gearing up for the pivotal November release of its Phase 3 global clinical trial results for its oral Alzheimer's treatment candidate, AR1001, setting its sights on U.S. FDA approval by 2028 and a 1 trillion won revenue milestone by 2030. Corporate editorial@mtimes.net (Song Jung-hee Reporter) https://mtimes.net/article/1128 https://mtimes.net/article/1128 Fri, 02 Oct 2026 00:05:00 GMT While the KOSPI finished September in positive territory, the broader market suffered a severe breadth contraction as heavyweights Samsung Electronics and SK hynix propped up the index while nearly 70% of listed issues declined. Markets editorial@mtimes.net (Kim Jeong-eun Reporter) https://mtimes.net/article/1117 https://mtimes.net/article/1117 Wed, 30 Sep 2026 23:01:34 GMT Behind Micron’s robust quarterly earnings lies an even stronger industry signal, as hyperscalers and AI data centers rush to lock in memory supply agreements stretching all the way to 2031. Corporate editorial@mtimes.net (Kim Jeong-eun Reporter) https://mtimes.net/article/1113 https://mtimes.net/article/1113 Wed, 30 Sep 2026 09:33:40 GMT Global technology giants are moving beyond conversational chatbots to always-on autonomous AI agents capable of executing tasks, scheduling, and data analysis in the background without user intervention. Industry editorial@mtimes.net (Kim Jeong-eun Reporter) https://mtimes.net/article/1348 https://mtimes.net/article/1348 Mon, 26 Oct 2026 21:48:11 GMT HanAll Biopharma’s autoimmune disease treatment batoclimab has received marketing approval in China following successful Phase 3 clinical trials, paving the way for milestone payments and sales royalties. Meanwhile, its next-generation candidate, imireprovat (IMVT-1402), is undergoing global Phase 3 trials for generalized myasthenia gravis, with early therapeutic responses also observed in rheumatoid arthritis. Corporate editorial@mtimes.net (Song Jung-hee Reporter) https://mtimes.net/article/1396 https://mtimes.net/article/1396 Fri, 30 Oct 2026 02:34:19 GMT Despite maintaining a robust operating margin above 50%, Hanmi Semiconductor’s third-quarter results fell nearly 30% short of market expectations, sparking a significant sell-off in its stock. Corporate editorial@mtimes.net (Kim Jeong-eun Reporter) https://mtimes.net/article/1382 https://mtimes.net/article/1382 Thu, 29 Oct 2026 05:10:49 GMT Despite posting record-high quarterly earnings, Samsung Electronics saw its shares tumble as the company deferred specific details on its share buyback and cancellation program until next January, sparking a wave of sell-offs following its earnings call. Corporate editorial@mtimes.net (Kim Jeong-eun Reporter) https://mtimes.net/article/1398 https://mtimes.net/article/1398 Fri, 30 Oct 2026 05:30:59 GMT Alteogen's subcutaneous (SC) delivery technology is driving significant revenue growth for Merck's Keytruda SC, with quarterly sales surging 79% to exceed $830 million. Corporate editorial@mtimes.net (Song Jung-hee Reporter) https://mtimes.net/article/1363 https://mtimes.net/article/1363 Wed, 28 Oct 2026 02:32:00 GMT SK hynix has effectively pre-sold its DRAM and HBM output through 2029, bolstered by a surge in AI data center investment. The company reported a record-breaking operating margin near 80%, fueled by long-term contracts with 14 major global tech clients. Corporate editorial@mtimes.net (Kim Jeong-eun Reporter) https://mtimes.net/article/1402 https://mtimes.net/article/1402 Fri, 30 Oct 2026 08:34:53 GMT Despite securing a blockbuster oral treatment through its multi-billion-dollar acquisition of Amicus Therapeutics, U.S. rare-disease specialist BioMarin has licensed a Phase 1/2 Fabry disease candidate jointly developed by Hanmi Pharmaceutical and GC Biopharma to target a broader patient demographic and challenge established intravenous therapies. Corporate editorial@mtimes.net (Kim Jeong-eun Reporter) https://mtimes.net/article/1388 https://mtimes.net/article/1388 Thu, 29 Oct 2026 09:56:27 GMT An obscure overseas investment group, Nexroc, has announced plans to acquire 14 companies, including K-pop agency JYP Entertainment and Japan's Avex, while proposing a tender offer for up to 50% of JYP. However, with no official negotiations initiated, unverified financial disclosures, and regulatory scrutiny mounting over its funding capabilities, market skepticism is intensifying. Corporate editorial@mtimes.net (Kim Jeong-eun Reporter) https://mtimes.net/article/1384 https://mtimes.net/article/1384 Thu, 29 Oct 2026 07:08:14 GMT LG Electronics' vehicle components division posts record third-quarter earnings, while cumulative orders for data center cooling solutions surpass 3 trillion won, accelerating the company's strategic shift toward business-to-business (B2B) markets and reducing its reliance on traditional home appliances. Corporate editorial@mtimes.net (Lee Kyung-hee Reporter) https://mtimes.net/article/1352 https://mtimes.net/article/1352 Tue, 27 Oct 2026 01:37:57 GMT HLB has unveiled long-term follow-up data from a Phase 2 trial of its pipeline liver cancer treatment, Rivoceranib, in rare thymic epithelial tumors at the European Society for Medical Oncology (ESMO 2026) Congress. The company is also gearing up for the US commercial launch of its newly FDA-approved cholangiocarcinoma treatment, Repertu. Corporate editorial@mtimes.net (Kim Jeong-eun Reporter) https://mtimes.net/article/1386 https://mtimes.net/article/1386 Thu, 29 Oct 2026 08:36:38 GMT Google’s parent company Alphabet saw its shares tumble post-earnings despite explosive growth in its cloud division, as slowing core advertising growth and heavy artificial intelligence infrastructure spending outpaced operating cash flow. Corporate editorial@mtimes.net (Song Jung-hee Reporter)